Injected abatacept may be a worthwhile treatment for certain patients with idiopathic inflammatory myositis (IIM), according to recent research.1 Patients with the rare autoimmune conditions involving inflammation of muscle (myositis) and other organ systems suffer widespread organ dysfunction, increased morbidity, physical disabilities and early death. Symptoms vary by subtype. For example, dermatomyositis (DM) involves muscle…
Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.
Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.
Nipocalimab, an investigational monoclonal antibody that blocks FcRn and reduces levels of circulating immunoglobulin G (IgG) antibodies, has received the FDA’s breakthrough therapy designation for the treatment of Sjögren’s disease.
Autologous hematopoietic stem cell transplantation (AHSCT) may improve the survival rate of patients with diffuse cutaneous systemic sclerosis (SSc), according to Georges et al. The single-arm clinical trial demonstrated the effectiveness of AHSCT and maintenance therapy. Researchers also identified potential risk factor of AHSCT in patients with low eGFR before transplantation.
The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.
Yalamanchili et al. describe how trends in disease-modifying anti-rheumatic drug (DMARD) use have evolved for insured, U.S. patients with juvenile idiopathic arthritis. Overall, the study found that from 2000 to 2022 in this patient population the use of biologic and targeted synthetic DMARDs rose, while the use of conventional synthetic DMARDs declined.
Based on decades of data from dietary and other lifestyle interventions, doctors have long known that significant weight loss can be an effective treatment for people who are overweight and have knee osteoarthritis (OA). One meta-analysis showed that OA pain, function and stiffness scores improved by 2% for every 1% in lost weight.1 But the…
“What can I eliminate from my diet to cure my arthritis?” is the question every client with arthritis asks me. Numerous case reports document patients who achieved lower markers of inflammation and reduced pain and stiffness associated with the removal of one or two food groups from a diet, but historically, no compelling evidence has…